Veracyte Inc VCYT:NASDAQ

Last Price$27.51Cboe Previous Close - Real-Time Last Sale as of 3:59PM ET 1/24/20
Cboe Real-Time Quotes
Today's Change0(0.00%)
Bid (Size)$26.40 (100)
Ask (Size)$28.66 (100)
Day Low / HighN/A - N/A
Volume277.4 K

Insider Trends: Insider at Veracyte Converts/Exercises Derivative Security, Sells for Taxes and Self, Buying Trend Remains Intact

4:24PM ET 12/04/2019 MT Newswires
On Dec 02, 2019, Chief Scientific & Med Officer, Dr Giulia C Kennedy, exercised options/derivative securities for 15,032 shares. A portion of these optioned shares (292 shares) were sold for tax obligations and an additional 15,619 shares were sold for $413,602. After the Form 4 filing with the SEC, Dr Kennedy owns 46,862 shares of company stock, with a market value, based on the prior-day closing price, of $1.23 million. In addition the company has granted Dr Kennedy stock options of which 72,057 are currently in the money and have an approximate value of $1,379,150 as of yesterday's closing price.

Over the last 90 days, prior to the date of this filing, there have been 22 insider transactions reported to the SEC for Veracyte. These transactions came from the activities of 4 individual insiders that resulted in a net acquisition of 12,337 company shares. This compares with the preceding 90-day window of time where there were 19 transactions from 7 insiders which resulted in the net acquisition of 22,030 shares.

This is a lower level of transactions than the peer group average in the 10-company Bio Diagnostics & Testing peer group over the last 90-day period. Peer group activity averaged 40.8 transactions per company, with company insiders acquiring on average 244,209 shares.

SEC Story Link http://www.sec.gov/Archives/edgar/data/1384101/000138410119000152/xslF345X03/wf-form4_157549452516750.xml